AMARIN CORP PLC\UK Restructuring Charges
AMARIN CORP PLC\UK (AMRN) reported Restructuring Charges of $40.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-29.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:RestructuringCharges · last filed 2026-07-29
- AMARIN CORP PLC\UK restructuring charges for the quarter ending 2026-06-30 was $40.00K, a 99.82% decline year-over-year.
- AMARIN CORP PLC\UK restructuring charges for the quarter ending 2026-03-31 was $3.32M.
- AMARIN CORP PLC\UK restructuring charges for the quarter ending 2025-12-31 was $4.06M.
- AMARIN CORP PLC\UK restructuring charges for the quarter ending 2025-09-30 was $9.41M.
- AMARIN CORP PLC\UK restructuring charges for fiscal 2025 was $36.23M.
- AMARIN CORP PLC\UK restructuring charges for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
- AMARIN CORP PLC\UK restructuring charges for fiscal 2023 was $10.97M, a 18.88% decline from fiscal 2022.
- AMARIN CORP PLC\UK restructuring charges for fiscal 2022 was $13.53M, a 1.39% decline from fiscal 2021.
| Period end | Restructuring Charges 3 month | Restructuring Charges 6 month | Restructuring Charges 9 month | Restructuring Charges 12 month |
|---|---|---|---|---|
| 2026-06-30 | $40.00K 10-Q · filed 2026-07-29 | $3.36M 10-Q · filed 2026-07-29 | $7.43M derived: sum of 3 quarters · filed 2026-07-29 | $16.83M derived: sum of 4 quarters · filed 2026-07-29 |
| 2026-03-31 | $3.32M 10-Q · filed 2026-04-29 | $7.39M derived: sum of 2 quarters · filed 2026-04-29 | $16.79M derived: sum of 3 quarters · filed 2026-04-29 | $39.55M derived: sum of 4 quarters · filed 2026-07-29 |
| 2025-12-31 | $4.06M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $13.47M derived: sum of 2 quarters · filed 2026-03-02 | $36.23M derived: sum of 3 quarters · filed 2026-07-29 | $36.23M 10-K · filed 2026-03-02 |
| 2025-09-30 | $9.41M 10-Q · filed 2025-10-29 | $32.16M derived: sum of 2 quarters · filed 2026-07-29 | $32.16M 10-Q · filed 2025-10-29 | |
| 2025-06-30 | $22.76M 10-Q · filed 2026-07-29 | $22.76M 10-Q · filed 2026-07-29 | ||
| 2024-12-31 | $0.00 10-K · filed 2026-03-02 | |||
| 2023-12-31 | $229.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $940.00K derived: sum of 2 quarters · filed 2026-03-02 | $10.97M derived: sum of 3 quarters · filed 2026-03-02 | $10.97M 10-K · filed 2026-03-02 |
| 2023-09-30 | $711.00K 10-Q · filed 2024-10-30 | $10.74M derived: sum of 2 quarters · filed 2024-10-30 | $10.74M 10-Q · filed 2024-10-30 | |
| 2023-06-30 | $10.03M 10-Q · filed 2024-07-31 | $10.03M 10-Q · filed 2024-07-31 | ||
| 2022-12-31 | -$180.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-12 | $3.31M derived: sum of 2 quarters · filed 2025-03-12 | $13.53M derived: sum of 3 quarters · filed 2025-03-12 | $13.53M 10-K · filed 2025-03-12 |
| 2022-09-30 | $3.49M 10-Q · filed 2023-11-01 | $13.71M derived: sum of 2 quarters · filed 2023-11-01 | $13.71M 10-Q · filed 2023-11-01 | $13.31M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-06-30 | $10.21M 10-Q · filed 2023-08-02 | $10.21M 10-Q · filed 2023-08-02 | $9.81M derived: sum of 3 quarters · filed 2024-02-29 | $23.93M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-03-31 | $0.00 10-Q · filed 2022-05-04 | -$398.00K derived: sum of 2 quarters · filed 2024-02-29 | $13.72M derived: sum of 3 quarters · filed 2024-02-29 | |
| 2021-12-31 | -$398.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $13.72M derived: sum of 2 quarters · filed 2024-02-29 | $13.72M 10-K · filed 2024-02-29 | |
| 2021-09-30 | $14.12M 10-Q · filed 2022-10-27 | $14.12M 10-Q · filed 2022-10-27 | ||
| 2021-03-31 | $0.00 10-Q · filed 2022-05-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B |